A Drug That Boosts Anandamide and Blocks TRPV1 Showed Antidepressant Effects in Rats
Injecting a compound that both blocks anandamide breakdown and inhibits TRPV1 receptors into the prefrontal cortex produced antidepressant effects in rats at a specific dose, partially through CB1 receptor activation.
Quick Facts
What This Study Found
This study tested the theory that anandamide produces a bell-shaped dose-response curve in depression because it activates two receptors with opposite effects: CB1 (antidepressant) and TRPV1 (pro-depressant).
Researchers administered N-arachidonoyl-serotonin (AA-5HT), a dual inhibitor that both prevents anandamide breakdown (by blocking FAAH) and blocks TRPV1 activation, directly into the prefrontal cortex of rats at three doses.
Only the middle dose (0.250 nmol) produced significant antidepressant-like effects in the forced swim test. The low and high doses had no effect, demonstrating a dose-dependent response.
The antidepressant effect of the effective dose was partially blocked when co-administered with the CB1 receptor inverse agonist rimonabant, confirming that the benefit worked at least partly through CB1 receptor activation.
Key Numbers
Three doses tested: 0.125, 0.250, 0.500 nmol. Only 0.250 nmol showed significant antidepressant effect. Rimonabant (1.6 micrograms) partially attenuated the effect.
How They Did This
Rats received direct injections of AA-5HT at three doses (0.125, 0.250, 0.500 nmol) into the medial prefrontal cortex. Behavior was assessed using the forced swim test. CB1 receptor involvement was confirmed by co-administering rimonabant (1.6 micrograms).
Why This Research Matters
This study provides experimental support for the dual-receptor theory of anandamide in depression: CB1 activation helps while TRPV1 activation hurts. By simultaneously targeting both, AA-5HT may represent a more refined approach to cannabinoid-based antidepressant therapy than simply boosting anandamide alone.
The Bigger Picture
The bell-shaped dose response curve that plagues cannabinoid research, where low and high doses are ineffective while a middle dose works, has been a major barrier to developing cannabinoid therapies. This study suggests the curve exists because anandamide activates competing receptor systems, and that blocking the counterproductive receptor (TRPV1) while enhancing the therapeutic one (CB1) could flatten this curve.
What This Study Doesn't Tell Us
The drug was injected directly into the brain, which is not a viable clinical administration route. The forced swim test is a screening tool that does not model all aspects of human depression. Only three doses were tested, and the optimal dose window may be narrow.
Questions This Raises
- ?Could a systemically administered FAAH/TRPV1 dual inhibitor produce the same antidepressant effects?
- ?Why did the high dose fail to produce antidepressant effects despite TRPV1 blockade?
- ?Could this dual-target approach work for human depression?
Trust & Context
- Key Stat:
- Only the middle dose produced antidepressant effects, supporting the bell-shaped dose-response theory
- Evidence Grade:
- Animal study with direct brain injection. Preliminary evidence providing mechanistic insight but far from clinical application.
- Study Age:
- Published in 2017.
- Original Title:
- A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats.
- Published In:
- Acta neuropsychiatrica, 29(6), 324-329 (2017)
- Authors:
- Kirkedal, Christian, Wegener, Gregers, Moreira, Fabricio, Joca, Sâmia Regiane Lourenco, Liebenberg, Nico
- Database ID:
- RTHC-01421
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could the endocannabinoid system be targeted to treat depression?
This study supports that idea but reveals the complexity: anandamide appears to act as both antidepressant (via CB1) and pro-depressant (via TRPV1). A drug that enhances the helpful pathway while blocking the harmful one showed antidepressant effects in rats.
Why does cannabis sometimes help and sometimes worsen mood?
This study suggests it may be because cannabinoids activate two receptor systems with opposing effects on mood: CB1 (beneficial) and TRPV1 (counterproductive). The net effect depends on the dose and which receptor system dominates.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-01421APA
Kirkedal, Christian; Wegener, Gregers; Moreira, Fabricio; Joca, Sâmia Regiane Lourenco; Liebenberg, Nico. (2017). A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats.. Acta neuropsychiatrica, 29(6), 324-329. https://doi.org/10.1017/neu.2016.68
MLA
Kirkedal, Christian, et al. "A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats.." Acta neuropsychiatrica, 2017. https://doi.org/10.1017/neu.2016.68
RethinkTHC
RethinkTHC Research Database. "A dual inhibitor of FAAH and TRPV1 channels shows dose-depen..." RTHC-01421. Retrieved from https://rethinkthc.com/research/kirkedal-2017-a-dual-inhibitor-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.